ClinicalTrials.gg
WithdrawnNCT04635111Updated Nov 4, 2026

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

An observational study in Hepatotoxicity and Tenosynovial Giant Cell Tumor, sponsored by Daiichi Sankyo. Withdrawn at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Daiichi Sankyo · Observational

How we know

Why this study was withdrawn
FDA release from PMR
Updated Nov 4, 2026Now WithdrawnPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Giant Cell Tumor of Tendon Sheath with a site in United States — 2 open to participants now, 5 under way, 2 of them phase 3. Giant Cell Tumor of Tendon Sheath · United States.

Started
2021
with 2 others
Observational
2 of 16
1 open now
Registered
11th of 16
by date
Lead sponsor
4 of 16
Daiichi Sankyo

Among the 16 studies in Giant Cell Tumor of Tendon Sheath with a site in United States, this one is one of 3 that started in 2021, is one of 2 observational ones, and was the 11th registered.

Giant Cell Tumor of Tendon Sheath

22 studies on the registry are indexed under Giant Cell Tumor of Tendon Sheath; 5 are open to participants now.

Browse Giant Cell Tumor of Tendon Sheath studies →

Open to participants now

2 of the 16 studies in Giant Cell Tumor of Tendon Sheath with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Giant Cell Tumor of Tendon Sheath studies recruiting now, 3 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Giant Cell Tumor of Tendon Sheath with a site in United States, or all of them as a file.
02

Study summary

A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon optional liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.

Read the detailed description

This FDA post-marketing requirement study will evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) for symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery, and who experience hepatotoxicity. An optional liver biopsy will be collected from enrolled patients for central laboratory analysis of macrophage and immune cell profiles to investigate possible mechanisms of the hepatotoxicity. Additionally, 4 blood samples will be collected to evaluate liver function, other relevant safety tests, peripheral immune cells, and for pharmacogenomic testing. Enrolled patients will be followed at least yearly for 10 years to assess long-term risk of hepatic failure.

03

Conditions studied

  • Hepatotoxicity
  • Tenosynovial Giant Cell Tumor

Keywords

  • Hepatotoxicity
  • Tenosynovial Giant Cell Tumor
  • Pexidartinib
  • TURALIO™
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery, who experience moderate or severe hepatotoxicity due to TURALIO™ (pexidartinib).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery
  • Age ≥18 years old
  • Emergence of at least one of the following liver test abnormalities due to TURALIO™ (pexidartinib) exposure:

    • (AST) or alanine aminotransferase (ALT) >3 × (ULN) with concurrent total (TBIL) >2 × ULN
    • Isolated TBIL >2 × ULN (excluding patients with Gilbert's syndrome)
    • Isolated AST or ALT >10 × ULN
    • Alkaline phosphatase (ALP) >2 x ULN with gamma-glutamyl transferase (GGT) >2 x ULN
  • Consent to study procedures, long-term safety follow-up, and use of data from the TURALIO™ (pexidartinib) Risk Evaluation and Mitigation Strategy (REMS) program

Exclusion criteria

Exclusion Criteria:

  • Not applicable
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Symptomatic TGCT Participants

    Adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery, and who experience moderate or severe hepatotoxicity due to use of TURALIO™ (pexidartinib).

    Drug: TURALIO™

Interventions

  • DrugPexidartinibStudies of PexidartinibPexidartinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This is a non-interventional, observational study to evaluate long-term risk of hepatic failure associated with TURALIO™ (pexidartinib) treatment. No study medication will be provided to the participants.

06

What researchers measure

Primary outcomes

  1. Frequency of Hepatic Failure After Discontinuation of TURALIO™ (pexidartinib)

    Hepatic failure is defined as severe liver injury with encephalopathy and impaired synthetic function (INR \>= 1.5) as well as liver transplant and hepatic-related death.

    Time frame: Baseline up to 10 years

Secondary outcomes

  1. Number of Participants With Liver Test Abnormalities

    Liver test abnormalities were defined as the following: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>3 × upper limit of normal (ULN) with concurrent total bilirubin (TBIL) \>2 × ULN; Isolated TBIL \>2 × ULN (excluding patients with Gilbert's syndrome); Isolated AST or ALT \>10 × ULN; Alkaline phosphatase (ALP) \>2 x ULN with gamma-glutamyl transferase (GGT) \>2 x ULN.

    Time frame: Baseline up to 10 years

  2. Number of Participants With A Liver Transplant

    Time frame: Baseline up to 10 years

  3. Number of Participants Experiencing Death

    Time frame: Baseline up to 10 years

07

Study locations

6 sites
  • Kamalesh K Sankhala MD INC
    Santa Monica, California 90403, United States
  • Sarcoma Oncology Research Center LLC
    Santa Monica, California 90403, United States
  • UCLA Hematology and Oncology
    Santa Monica, California 90404, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • OSU - James Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Kelsey Seybold Clinic - Pearland
    Houston, Texas 77014, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

Access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2021 to primary completion in Jul 2026, 66 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Jun 2036 → Jul 2026 and completion Jun 2036 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2020
First posted
Nov 18, 2020
StartActual
Jan 7, 2021
Primary completionActual
Jul 24, 2026was Jun 2036
CompletionActual
Jul 24, 2026was Jun 2036
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Withdrawn FDA release from PMR
changed Nov 4, 2026
Sites
2 sites removed
Show 2 removed
  • The Oncology Institute of Hope and Innovation · Whittier, United States
  • Montefiore Medical Center · New York, United States
Nov 4, 2026
Primary completion
Jun 1, 2036→Jul 24, 2026 (actual)
Nov 4, 2026
Study completion
Jun 1, 2036→Jul 24, 2026 (actual)
Nov 4, 2026
Enrollment
30 (estimated)→0 (actual)
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Recruiting→Withdrawn
    Why stopped FDA release from PMR
    2 sites removed
    Show 2 removed
    • The Oncology Institute of Hope and Innovation · Whittier, United States
    • Montefiore Medical Center · New York, United States
    Primary completion Jun 1, 2036→Jul 24, 2026 (now actual)
    Study completion Jun 1, 2036→Jul 24, 2026 (now actual)
    Enrollment 30 (estimated)→0 (actual)
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04635111
Lead sponsor
Daiichi Sankyo
Responsible party
Sponsor
First posted
Nov 18, 2020
Start date
Jan 7, 2021
Primary completion
Jul 24, 2026
Completion
Jul 24, 2026
Last update
Nov 4, 2026

Study contacts

Global Clinical Leader
study director · Daiichi Sankyo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion